The lifting of the FDA’s clinical hold on Neurizon’s drug will pave the way for its investigation in the HEALEY-ALS trial.

Italy-based biotech firm NanoPhoria Bioscience has announced the initial closing of its Series A funding round, raising ...

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m ...

Chiesi Group and Arbor have formed an exclusive partnership and licensing deal for the latter’s investigational gene editing ...

Induced pluripotent stem cells (iPSCs) have the potential to usher in a new era of transformative medical treatments, capable ...